Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy

Tomoyuki Suzuki, Shunsuke Kawamoto, Kiichiro Kumagai, Osamu Adachi, Keisuke Kanda, Masaaki Ishikawa, Yoko Okitsu, Hideo Harigae, Shin Kurosawa, Yoshikatsu Saiki

研究成果: Article査読

6 被引用数 (Scopus)

抄録

We herein report our experience of successfully managing the hemostatic system by controlling serum factor IX levels throughout the perioperative period in a patient with hemophilia B. Coronary artery bypass grafting with cardiopulmonary bypass was planned for a 52-year-old man with moderate severity of hemophilia B. During surgery, recombinant factor IX (rFIX; BeneFIX® Pfizer Japan inc., Tokyo, Japan) was administered by bolus infusion followed by continuous infusion as per the guidelines of the Japanese Society on Thrombosis and Hemostasis. The operative course was uneventful without any considerable bleeding or complications.

本文言語English
ページ(範囲)481-483
ページ数3
ジャーナルGeneral thoracic and cardiovascular surgery
64
8
DOI
出版ステータスPublished - 2016 8 1

ASJC Scopus subject areas

  • 外科
  • 呼吸器内科
  • 循環器および心血管医学

フィンガープリント

「Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル